73
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Quality assessment of meta-analyses of RCTs of pharmacotherapy in major depressive disorder

, , , &
Pages 477-484 | Accepted 01 Dec 2003, Published online: 05 Feb 2004
 

SUMMARY

Background: Meta-analyses (MAs) of randomized controlled trials (RCTs) have the potential to provide the highest level of evidence, but the quality of published MAs has not been systematically assessed. Therefore, we determined the quality of reporting in MAs of RCTs of pharmacotherapy for major depressive disorder (MDD) in adults (18–65 years) without co-morbidities and examine trends over time.

Methods: MEDLINE, EMBASE, Healthstar, Psychlit and Cochrane databases were searched (1980–2002) by 4 independent reviewers for MAs of RCTs. Articles meeting inclusion criteria were blinded. Inter-rater reliability (kappa) was evaluated using a test–retest strategy on 4 articles. Quality was assessed using the QUOROM checklist. Time trends were evaluated by calculating Spearman's rho.

Results: One hundred articles were identified, 68 were excluded [co-morbidities (9), inappropriate comparator (13), inappropriate outcome (15), article not available (5), inappropriate patient population (15), and inappropriate study design (11)]; 32 were included. Initial kappa was 0.81 ( p < 0.05). After resolution of disagreements, the test–retest reliability was significant (kappa = 0.89; p < 0.05). The mean overall quality score was 50.2% (SD 15.8%, range = 16.7–88.9%). The overall score for Titles was very poor (22%), Abstracts (40%) and Methods (49%) were poor, while overall Results score was minimally acceptable (54%). Good quality scores were found for Introduction (91%) and Discussion (97%). No time trends were identified using Spearman's correlation analysis (rho 0.05; p = 0.79). The Mann–Whitney U test ( p = 0.74) did not detect a difference in quality of articles published before and after the QUOROM.

Conclusion: Despite quality guidelines, the average quality of published MAs of antidepressants is barely acceptable (50.2%). A need exists for adherence to standardized reporting and quality guidelines.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.